INVO Fertility, Inc. (IVF) announced the issuance of a U.S. patent covering a modified version of its proprietary INVOcell device. The patent became effective on February 10, 2026, extending intellectual property protection through 2040.
The INVOcell device is the world's first FDA-cleared intravaginal culture (IVC) system, enabling fertilization and early embryo development to occur within a woman's body. The newly patented modification incorporates a simplified design with a single main chamber, developed based on clinical feedback, to enhance usability in assisted reproductive care.
The company announced a 1-for-8 reverse stock split on November 28, 2025.
IVF is currently trading at $1.21, up 9.08%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.